GeneDx Holdings is facing a securities class action lawsuit following a 49% single-day stock decline on May 5, 2026, after the company reported disastrous first-quarter results that included a $31.2 million impairment charge on its Fabric Genomics unit, representing about 94% of the $33.2 million cash paid for the acquisition just one year earlier. The lawsuit, filed by shareholder rights firm Hagens Berman, seeks to represent investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026, and alleges the company made false and misleading statements about the importance of Fabric Genomics, the durability of its average reimbursement rate, and its growth prospects. GeneDx's first-quarter 2026 net loss increased tenfold year-over-year, driven largely by the Fabric Genomics business, which missed revenue expectations by $2.5 million, while the company's average reimbursement rate fell about $200 short of prior assurances and full-year revenue guidance was slashed by 12%. The lead plaintiff deadline is August 3, 2026.
GeneDx Holdings Corp.Securities class action lawsuit alleging false and misleading statements, with lead plaintiff deadline approaching.